Doxorubicin (DOX) is a chemotherapeutic agent frequently used for the treatment of a variety
of tumor types, such as breast cancer. Despite the long history of DOX, the mechanistic …

The antineoplastic drug doxorubicin is capable of generating a variety of free radical species
in subcellular systems and this capacity has been considered critical for its antitumor action …

NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of
doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an …

Abstract Polymer micelles are rapidly becoming a powerful nanomedicine platform for
cancer therapeutic applications due to their small size (10–100 nm), in vivo stability, ability to …

Anticancer drugs reversibly bound to magnetic fluids (ferrofluids) could be concentrated in
locally advanced tumors by magnetic fields that are arranged at the tumor surface outside of …

Abstract Objectives Doxorubicin (Dox) belongs to the anthracycline drug classification and is
a widely administered chemotherapeutic. However, Dox use in therapy is limited by its …

The anticancer agent Adriamycin (ADR) has long been recognized to induce a dose-limiting
cardiotoxicity. Numerous studies have attempted to characterize and elucidate the …

The narrow therapeutic index of anticancer drugs presents a clinical dilemma when these
agents are administered to patients with impaired or unstable renal function. The purpose of …

Glucuronidation is a major metabolic pathway for a large number of drugs in humans.
Conjugation of drugs and other chemicals with glucuronic acid is catalyzed by the multigene …

1. Little information is available about the pharmacokinetic interactions of anticancer drugs
in man. However, clinically significant drug interactions do occur in cancer chemotherapy …